Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion

Detalles Bibliográficos
Autores principales: Thavaneswaran, Subotheni, Chan, Wei Yen, Asghari, Ray, Grady, John P., Deegan, Maegan, Jansen, Valerie M., Thomas, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812631/
https://www.ncbi.nlm.nih.gov/pubmed/36455193
http://dx.doi.org/10.1200/PO.22.00263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812631/
https://www.ncbi.nlm.nih.gov/pubmed/36455193
http://dx.doi.org/10.1200/PO.22.00263

Ejemplares similares